Clinical Trials Directory

Trials / Completed

CompletedNCT00261911

A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety.

A 12 Month Study to Assess Safety and Efficacy of Meridia (Sibutramine Hydrochloride Monohydrate) 10 and 15 mg in Obese Adolescents

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
498 (actual)
Sponsor
Abbott · Industry
Sex
All
Age
12 Years – 16 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to assess the effectiveness of sibutramine on weight loss, reduction in body size and improvement in metabolic risk factors and safety in obese adolescents.

Conditions

Interventions

TypeNameDescription
DRUGsibutramine

Timeline

Start date
2000-07-01
Completion
2002-02-01
First posted
2005-12-06
Last updated
2007-08-31

Source: ClinicalTrials.gov record NCT00261911. Inclusion in this directory is not an endorsement.

A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety. (NCT00261911) · Clinical Trials Directory